Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.
Most-favoured-nation pricing models could reduce US Medicare spending by approximately $6.4 billion annually for 195 brand-name drugs.
- Why it matters: High drug prices in the US pose a significant financial burden, and implementing fairer international pricing could help control costs and improve affordability.
- What they did: The study modeled the impact of GLOBE and GUARD payment models by linking Medicare data with international prices and rebates for 195 drugs, estimating potential savings.
- The result: Estimated reductions in Medicare spending exceeded annual sales in many referenced countries, but potential savings could decrease if manufacturers with special agreements are exempted or if the reference basket narrows.